About EJOP

In 2000, in Prague, Czech Republic, the European Society of Oncology Pharmacy (ESOP) was established as a result of the actions undertaken by a group of European activists in oncology pharmacy who acknowledged the importance of continuous education, specialisation and knowledge exchange. Active contribution of oncology and hospital pharmacy professionals from 29 countries ensures the success of the society in achieving the initially stated aim of determining the optimal medical treatment for cancer patients, thereby improving the quality of their lives.

The European Journal of Oncology Pharmacy (EJOP) evolved from the electronic newsletter to its current print format with its first bi-annual issue published in January 2007. Starting from 2010, EJOP is published quarterly, and distributed to ESOP members. EJOP is accessible via www.ejop.eu.

Mission Statement/Editorial Objectives

• To provide information on professional topics to practising oncology pharmacists and technicians
• To offer a publishing platform to share professional achievements
• To disseminate information on recent scientific progress and give scientific overviews on oncology, particularly oncology pharmacy matters where the knowledge has moved forward significantly
• To provide diagnostic, therapeutic, chemical, pharmacological, toxicological and chemical background specifically related to oncology pharmacy
• To offer a regular communication channel to ESOP members and others quarterly
• To strengthen the profile of ESOP members’ professional status

Scope and Profile

The European Journal of Oncology Pharmacy (EJOP), published quarterly, sets out to offer a professional communication platform to European oncology pharmacy practitioners. As the official journal of the European Society of Oncology Pharmacy (ESOP), the scope of EJOP is to satisfy ESOP members’ needs in terms of improvement on professional standard, setting guidelines, further education and sharing practice experience. EJOP offers ESOP members an insight into the differences and commonalities of oncology pharmacy standards and training, as well as the opportunities to learn the unique benefits and advantages from the different oncology pharmacy practitioners.

• Circulation of EJOP is more than 2,000 ESOP members (still growing), with a market penetration in 33 countries
• France, Germany and the UK represent 65% of the total circulation
• EJOP is distributed at the annual ESOP Congress in January and at the major annual European oncology congress in September/October

Top 10 Countries in EJOP 2009 Circulation

EJOP was first published in 2007 as a communication platform for oncology pharmacists and pharmacy technicians. EJOP aims to provide regular updates to oncology pharmacy practitioners and technicians for their continuous learning and practice improvement and to upkeep their knowledge and skills in the healthcare setting.

Practitioners in the area of oncology pharmacy who would like to author papers on topics relating to their profession and the manuscripts comply with the editorial policy of EJOP are welcome to submit their manuscripts for assessment and approval for publication in EJOP.

Those interested can download the Guidance for Authors for manuscript preparation. For further information contact the editorial office of EJOP using contact form.

EJOP is distributed free to ESOP members. Subscription is available to individuals, institutions, universities, hospitals, corporations and students who are not members of ESOP.

Subscription rates cover four issues of EJOP per year.

For further information on EJOP journal and website (www.ejop.eu) advertising packages, rates and discounts, website traffic information as well as EJOP subscriptions, please contact Ms Lasia Tang, Publisher: Tel: +32 474989572, Fax: +32 14 583048, email: lasia.tang@ppme.eu